The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Cancer Biomarkers: Can We Turn Recent Failures into Success?
Open accessAbstract
Disease biomarkers are used widely in medicine. But very few biomarkers are useful for cancer diagnosis and monitoring. Over the past 15 years, major investments have been made to discover and validate cancer biomarkers. Despite such investments, no new major cancer biomarkers have been approved for clinical use for at least 25 years. In the last decade, many reports have described new cancer biomarkers that promised to revolutionize the diagnosis of cancer and the management of cancer patients. However, many initially promising biomarkers have not been validated for clinical use. In this commentary, a plethora of parameters before sample analysis, during sample analysis, and after sample analysis that can complicate biomarker discovery and validation and lead to "false discovery" are discussed. Several examples of biomarker discoveries that were published in high-profile journals are also presented, as well as why they were not validated and the lessons learned from these false discoveries, so that similar mistakes can be avoided in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: EPCA-2: A Highly Specific Serum Marker for Prostate Cancer
Leman, E. S., Cannon, G. W., Trock, B. J., Sokoll, L. J., Chan, D. W., Mangold, L. A., Partin, A. W., & Getzenberg, R. H. (2007) · Urology · doi:10.1016/j.urology.2007.01.097 · Cited by 125
RetractedLeman, E. S., Schoen, R. E., Weissfeld, J. L., Cannon, G. W., Sokoll, L. J., Chan, D. W., & Getzenberg, R. H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0649 · Cited by 51
RetractedUse of proteomic patterns in serum to identify ovarian cancer
Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07746-2 · Cited by 3,236
Phases of Biomarker Development for Early Detection of Cancer
Pepe, M. S., Etzioni, R., Feng, Z., Potter, J. D., Thompson, M. L., Thornquist, M., Winget, M., & Yasui, Y. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.14.1054 · Cited by 1,686
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Self-citationPrediction of cancer outcome with microarrays: a multiple random validation strategy
Michiels, S., Koscielny, S., & Hill, C. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17866-0 · Cited by 1,025
Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD Initiative
Bossuyt, P. M., Reitsma, J. B., Bruns, D. E., Gatsonis, C. A., Glasziou, P. P., Irwig, L. M., Lijmer, J. G., Moher, D., Rennie, D., de Vet, H. C. W., et al. (2003) · Clinical Chemistry · doi:10.1373/49.1.1 · Cited by 862
Strategies for discovering novel cancer biomarkers through utilization of emerging technologies
Kulasingam, V., & Diamandis, E. P. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1187 · Cited by 771
Self-citationDifferential exoprotease activities confer tumor-specific serum peptidome patterns
Villanueva, J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26022 · Cited by 741
Pepe, M. S., Feng, Z., Janes, H., Bossuyt, P. M., & Potter, J. D. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn326 · Cited by 717
Cited by
Colorectal Carcinoma: A General Overview and Future Perspectives in Colorectal Cancer
Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010197 · Cited by 1,525
Systems biology and multi-omics integration: viewpoints from the metabolomics research community
Pinu, F. R., Beale, D. J., Paten, A. M., Kouremenos, K., Swarup, S., Schirra, H. J., & Wishart, D. (2019) · Metabolites · doi:10.3390/metabo9040076 · Cited by 723
Comprehensive literature review and statistical considerations for microarray meta-analysis
Tseng, G. C., Ghosh, D., & Feingold, E. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr1265 · Cited by 526
Beyond PSA: The Next Generation of Prostate Cancer Biomarkers
Prensner, J. R., Rubin, M. A., Wei, J. T., & Chinnaiyan, A. M. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003180 · Cited by 472
Translation of proteomic biomarkers into FDA approved cancer diagnostics: issues and challenges
Füzéry, A. K., Levin, J., Chan, M. M., & Chan, D. W. (2013) · Clinical Proteomics · doi:10.1186/1559-0275-10-13 · Cited by 428
Metadata
- Authors
- Diamandis, E. P.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-08-12
- Volume
- 102
- Issue
- 19
- Pages
- 1462-1467
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2142846876
- Cited by
- 376
- References
- 29
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cancer Biomarkers: Can We Turn Recent Failures into Success? https://app.cochat.ai/papers/10.1093/jnci/djq306
- The paper
- Diamandis, E. P. (2010). Cancer Biomarkers: Can We Turn Recent Failures into Success? JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djq306
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.